Prostaglandins for preventing postpartum haemorrhage

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Public Health

Background:

• Prostaglandins are typically used for postpartum hemorrhage (PPH) as a last resort.
• Misoprostol, an inexpensive prostaglandin E1 analogue, is proposed for routine third-stage labor management.
• Evidence on prophylactic prostaglandin use in labor is being reviewed.

Purpose of the Study:

• To evaluate the effectiveness and safety of prophylactic prostaglandin administration during the third stage of labor.
• To compare prostaglandin agents against other uterotonics or placebo for PPH prevention.
• To analyze primary outcomes including blood loss exceeding 1000 mL and additional uterotonic use.

Main Methods:

• A systematic review of randomized controlled trials was conducted.
• Searches were performed on the Cochrane Pregnancy and Childbirth Group's Trials Register.
• Two independent reviewers assessed trial eligibility, quality, and extracted data.

Main Results:

• Oral or sublingual misoprostol significantly reduced severe PPH and blood transfusions compared to placebo.
• Compared to injectable uterotonics, oral misoprostol showed a higher risk of severe PPH and additional uterotonic use.
• Misoprostol use was linked to increased shivering and elevated body temperature.

Conclusions:

• Oral or sublingual misoprostol shows promise in decreasing postpartum blood loss compared to placebo.
• Misoprostol's benefits may vary depending on concurrent labor management strategies.
• Further research should focus on optimal dosing, administration routes, and implementation in low-resource settings.